| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/16/2006 | US7045536 Compound having anti-viral activity |
| 05/16/2006 | US7045535 Respiratory system disorders |
| 05/16/2006 | US7045534 Methods of reducing angiogenesis |
| 05/16/2006 | US7045533 Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout |
| 05/16/2006 | US7045532 ACE-2 modulating compounds and methods of use thereof |
| 05/16/2006 | US7045531 Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator |
| 05/16/2006 | US7045530 alzheimer's disease; schizophrenia |
| 05/16/2006 | US7045529 Imidazopyrimidinyl and imidazopyri dinyl derivatives |
| 05/16/2006 | US7045528 Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use |
| 05/16/2006 | US7045527 Piperidine derivatives |
| 05/16/2006 | US7045526 Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them |
| 05/16/2006 | US7045525 Use of (R)-peniciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases |
| 05/16/2006 | US7045524 Bactericides; infection therapy; topical administering |
| 05/16/2006 | US7045523 Administering a synergistic mixture of Imatinab and a telomerase inhibitor, e.g., telomestatin, for the delay of progression or treatment of leukemia or Imatinib-resistant leukemia; antiproliferative agents |
| 05/16/2006 | US7045522 8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives technical field |
| 05/16/2006 | US7045521 Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents |
| 05/16/2006 | US7045520 Opioid receptor active compounds |
| 05/16/2006 | US7045519 Pyrimidine or pyridine derivatives |
| 05/16/2006 | US7045518 Compounds for treatment of AIDS with enzyme inhibitors |
| 05/16/2006 | US7045517 Triazine compounds |
| 05/16/2006 | US7045516 Irritable bowel diosrders; gastrointestinal disorders; diarrhea |
| 05/16/2006 | US7045515 Anticholesterol agents |
| 05/16/2006 | US7045514 Therapeutic heterocyclic compounds |
| 05/16/2006 | US7045513 DHEA composition and method |
| 05/16/2006 | US7045511 Fosinopril formulation |
| 05/16/2006 | US7045510 Using dextran, or derivative thereof |
| 05/16/2006 | US7045509 Proteins and nucleic acids encoding same |
| 05/16/2006 | US7045508 Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products |
| 05/16/2006 | US7045507 Substituted tetracycline compounds as synergistic antifungal agents |
| 05/16/2006 | US7045506 stability; discoloration inhibition, odorless; applying to hair, skin |
| 05/16/2006 | US7045499 Therapeutic agent |
| 05/16/2006 | US7045497 Use of peptide |
| 05/16/2006 | US7045347 Helper dependent adenovirus vectors based on integrase family site-specific recombinases |
| 05/16/2006 | US7045329 Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy |
| 05/16/2006 | US7045323 Glutathione reductase for therapy and prophylaxis of aids |
| 05/16/2006 | US7045318 Recombinant fusion proteins to growth hormone and serum albumin |
| 05/16/2006 | US7045315 Methods for modulating expression of exogenous genes in mammalian systems |
| 05/16/2006 | US7045283 Detecting preferential ligands in cell; obtain cell, incubate with reporter molecules, detect reporter in cell |
| 05/16/2006 | US7045282 Measurement using urinary catalytic iron; administering iron chelate |
| 05/16/2006 | US7045155 Phytooestrogen selected from genistein, daidzein; for promoting health in cases of cancer, pre-menstrual syndrome, menopause or hypercholesterolaemia |
| 05/16/2006 | US7045152 Pulmonary disorders in which the S-nitrosoglutathione(GSNO) pool or glutathione pool in the lung is depleted and where reactive oxygen species in lung are increased, are treated by delivering into the lung an agent causing repletion of GSNO |
| 05/16/2006 | US7045151 Method and composition for improving fertility health in female and male animals and humans |
| 05/16/2006 | US7045147 Therapy for congestive heart failure; administering by mouth |
| 05/16/2006 | US7045145 Multilayer; backing layer, solid absorption adhesive polymer matrix ; controlled dosage of estrogen and progestin |
| 05/16/2006 | US7045143 Mixture of lecithin and fatty acid; antiinflammatory agents; diseases of lipid metabolism; immunology disorders |
| 05/16/2006 | US7045140 Therapeutic delivery of carbon monoxide |
| 05/16/2006 | US7045139 Process for manufacture of quaternary ammonium tosylate salts of cinnamidoalkylamines and/or benzamidoalkylamines |
| 05/16/2006 | US7045121 Ophthalmic compositions for lubricating eyes and methods for making and using same |
| 05/16/2006 | US7045120 Photoprotective/cosmetic compositions comprising sulfonic/hydrophobic amphiphilic polymers |
| 05/16/2006 | US7045119 Delivery of diazepam through an inhalation route |
| 05/16/2006 | US7045118 Delivery of compounds for the treatment of migraine through an inhalation route |
| 05/16/2006 | US7045095 Use of low molecular weight amino alcohols in ophthalmic compositions |
| 05/16/2006 | CA2366856C Formulation comprising testosteron undecanoate and castor oil |
| 05/16/2006 | CA2291650C Novel heteroethynylene compounds and pharmaceutical and cosmetic compositions containing same |
| 05/16/2006 | CA2244903C Hydroxamic acid derivatives for use with the treatment of diseases related to connective tissue degradation |
| 05/16/2006 | CA2242571C Amino compounds and angiotensin iv receptor agonists |
| 05/16/2006 | CA2237752C Novel substituted aryl compounds useful as modulators of acetylcholine receptors |
| 05/16/2006 | CA2227386C Piperazine derivatives and their use as 5-ht1a antagonists |
| 05/16/2006 | CA2197628C Substituted thiophenylalkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 05/16/2006 | CA2192916C Substituted chromanylsulfonyl(thio)ureas, processes for their preparation, their use in pharmaceutical preparations, and pharmaceutical preparations comprising them |
| 05/16/2006 | CA2192797C Indolinone compounds for the treatment of disease |
| 05/16/2006 | CA2192535C 2-naphtamides derivatives and therapeutic uses thereof |
| 05/15/2006 | CA2484691A1 A nutriceutical composition for the correction of impaired endothelium-dependent arterial vasomotor response |
| 05/12/2006 | CA2487564A1 Folic acid-chitosan-dna nanoparticles |
| 05/11/2006 | WO2006050520A2 Antipyretic compositions and methods |
| 05/11/2006 | WO2006050514A1 Gabapentin prodrug sustained release oral dosage forms |
| 05/11/2006 | WO2006050511A2 Butyrophenomenes and sigma-1 receptor antagonists protect against oxidatives-stress |
| 05/11/2006 | WO2006050509A2 Amorphous and polymorphic forms of telmisartan sodium |
| 05/11/2006 | WO2006050506A1 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 05/11/2006 | WO2006050501A2 Novobiocin analogues as anticancer agents |
| 05/11/2006 | WO2006050498A2 Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| 05/11/2006 | WO2006050489A2 Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions |
| 05/11/2006 | WO2006050480A2 Substituted pyridines with activity on syk kinase |
| 05/11/2006 | WO2006050461A1 Use of an mtor inhibitor in treatment of uterine leiomyoma |
| 05/11/2006 | WO2006050458A2 Tadalafil crystal forms and processes for preparing them |
| 05/11/2006 | WO2006050457A2 Methods and compositions for treating chronic lymphocytic leukemia |
| 05/11/2006 | WO2006050451A2 Methods and compositions to treat motor neuron disease |
| 05/11/2006 | WO2006050447A2 Apogossypolone and the uses thereof |
| 05/11/2006 | WO2006050432A1 Methods for regulating weight and size of animals with glycin |
| 05/11/2006 | WO2006050402A1 Estrogen receptor modulators |
| 05/11/2006 | WO2006050389A2 Pyridazine compounds, compositions and methods |
| 05/11/2006 | WO2006050381A2 Antiviral composition |
| 05/11/2006 | WO2006050373A2 Methods and compositions for modulating apoptosis |
| 05/11/2006 | WO2006050359A2 Pyridazine compounds and methods |
| 05/11/2006 | WO2006050328A1 Improved quenching methods for red blood cell inactivation process |
| 05/11/2006 | WO2006050315A2 Aliphatic amine polymer salts for tableting |
| 05/11/2006 | WO2006050314A2 Once a day formulation for phosphate binders |
| 05/11/2006 | WO2006050303A2 Intravaginal treatment of vaginal infections with metronidazole compositions |
| 05/11/2006 | WO2006050270A2 Compositions and methods for treating hyperproliferative disorders |
| 05/11/2006 | WO2006050265A2 Ceramides and apoptosis-signaling ligand |
| 05/11/2006 | WO2006050250A2 Dose forms comprising vx-950 and their dosage regimen |
| 05/11/2006 | WO2006050249A1 Diaminotriazole compounds useful as inhibitors of protein kinases |
| 05/11/2006 | WO2006050246A2 Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles, their manufacturing and their use for diagnostics and therapy |
| 05/11/2006 | WO2006050241A1 Prostaglandin ep4 antagonists |
| 05/11/2006 | WO2006050239A2 Muscarinic acetylcholine receptor antagonists |
| 05/11/2006 | WO2006050212A1 Substituted carboxylic acids |
| 05/11/2006 | WO2006050178A2 Multiple layer coating composition |
| 05/11/2006 | WO2006050170A2 Medical devices containing rapamycin analogs |
| 05/11/2006 | WO2006050165A2 Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| 05/11/2006 | WO2006050162A2 Imidazole derivatives |